Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Certara, Inc. is a global biosimulation and model-informed drug development (MIDD) company that provides software and technology-enabled services to pharmaceutical, biotechnology, and regulatory organizations. The company operates at the intersection of life sciences, data science, and regulatory science, helping clients improve decision-making across drug discovery, development, and regulatory approval. Certara’s offerings are used to simulate how drugs behave in the human body, optimize clinical trial design, and support regulatory submissions.
Founded in 2008 through the merger of Tripos International and Pharsight Corporation, Certara has evolved from specialized pharmacometrics software providers into an integrated platform company. Its business is driven primarily by recurring software subscriptions and long-term services engagements, supported by deep regulatory credibility, including frequent use of its tools in submissions to the U.S. Food and Drug Administration (FDA) and other global regulators. The company positions itself as a leader in MIDD, a methodology increasingly encouraged by regulatory agencies to improve efficiency and reduce development risk.
Business Operations
Certara operates through two primary business segments: Software and Services. The Software segment includes industry-standard biosimulation and data analytics platforms such as Phoenix, Simcyp, and Pirana, which are used for pharmacokinetic/pharmacodynamic modeling, population analysis, and drug–drug interaction prediction. These products are typically sold via annual or multi-year subscriptions, generating predictable recurring revenue.
The Services segment provides scientific consulting, regulatory writing, and data analytics through multidisciplinary teams of pharmacometricians, clinicians, and regulatory experts. These services support clinical trial simulation, dose optimization, and regulatory strategy. Certara serves a global customer base that includes large pharmaceutical companies, emerging biotech firms, academic institutions, and government agencies, with revenue generated from both domestic and international operations.
Strategic Position & Investments
Certara’s strategy centers on expanding adoption of MIDD across the drug development lifecycle and scaling its technology platform through both organic innovation and targeted acquisitions. The company has invested heavily in artificial intelligence and advanced analytics to enhance predictive modeling capabilities and integrate real-world data into development workflows. This strategy aligns with regulatory trends that increasingly support quantitative modeling to streamline approvals.
Growth has also been supported by acquisitions that expand scientific depth and service capabilities, including Applied BioMath and P-Pharm, which strengthened Certara’s expertise in systems pharmacology and regulatory science. Certara continues to invest in next-generation biosimulation tools and cloud-enabled platforms, aiming to embed its software more deeply into clients’ R&D and regulatory processes.
Geographic Footprint
Certara is headquartered in the United States, with principal offices in Princeton, New Jersey. The company maintains a significant international presence across Europe, Asia-Pacific, and the United Kingdom, supporting global pharmaceutical development programs and regulatory submissions.
Its global workforce enables collaboration with regulatory agencies and life sciences companies in major drug development hubs, including North America, Western Europe, and Japan. Certara’s international operations are integral to serving multinational clients and supporting submissions to regulators such as the FDA, EMA, and PMDA.
Leadership & Governance
Certara is led by an executive team with extensive experience in life sciences, software, and regulatory science. Leadership emphasizes scientific rigor, regulatory credibility, and long-term partnerships with customers, with a strategic vision focused on making model-informed decision-making a standard practice in drug development.
Key executives include:
- William F. Feehery – Chief Executive Officer
- Leif Pedersen – President, Software
- David A. Kaltenbach – Chief Financial Officer
- Sanjiv Narayan – President, Services
- John R. Lewis – Chief Scientific Officer
The company is publicly traded on the Nasdaq Global Select Market under the ticker CERT and operates under a board governance structure consistent with U.S. public company standards, with oversight of strategy, risk management, and capital allocation.